![Logo](/assets/logo-d3f1fdf60522f0983e71f9fcc720cb7da5b55c0b748ed5bded3d2fbf81387bf0.png)
CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 197791-197929
Annnotations
CORD-19-Sentences
{"project":"CORD-19-Sentences","denotations":[{"id":"T78495","span":{"begin":0,"end":138},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The treatment of choice for acute attacks and prophylaxis appears to be the C1 inhibitor concentrate, which is not yet licensed in the US."}
Epistemic_Statements
{"project":"Epistemic_Statements","denotations":[{"id":"T352","span":{"begin":0,"end":138},"obj":"Epistemic_statement"}],"text":"The treatment of choice for acute attacks and prophylaxis appears to be the C1 inhibitor concentrate, which is not yet licensed in the US."}
CORD-19_Custom_license_subset
{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T33","span":{"begin":0,"end":138},"obj":"Sentence"}],"text":"The treatment of choice for acute attacks and prophylaxis appears to be the C1 inhibitor concentrate, which is not yet licensed in the US."}